Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Net Revenues	$ 10,899	$ 5,562
Operating Expenses
Cost of sales (excluding depreciation and amortization)	2,622	2,408
Research and development	376	296
Selling, general and administrative	3,703	2,310
Depreciation and amortization	703	145
Total Operating Expenses	7,404	5,159
Operating Income	3,495	403
Other Income/(Expense)
Interest expense	0	(93)
Other income/(expense)	29	(50)
Income Before Provision for Income Taxes	3,524	260
Provision for income taxes	(165)	0
Net Income	3,359	260
Computation of Income/(Loss) Attributable to Common Stockholders:
Net Income	3,359	260
Preferred stock dividends	0	(2,604)
Income/(Loss) Attributable to Common Stockholders	$ 3,359	$ (2,344)
Basic and Diluted Earnings/(Loss) Per Share:
Basic Earnings/(Loss) Per Share (in dollars per share)	$ 0.33	$ 0	[1]
Diluted Earnings/(Loss) Per Share (in dollars per share)	$ 0.33	$ 0	[1]
Basic Weighted-Average Shares Outstanding (in shares)	9,991	0	[1]
Diluted Weighted-Average Shares Outstanding (in shares)	10,001	0	[1]

[1] Earnings/(loss) per common share is not calculable because common shareholders from ANIP Acquisition Company did not receive consideration from the June 19, 2013 Merger with BioSante. See Note 4 for further details.